The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust
J Infect
.
2021 Apr;82(4):84-123.
doi: 10.1016/j.jinf.2020.11.004.
Epub 2020 Nov 12.
Authors
Thomas Gardiner
1
,
Graham Cooke
2
,
Sarah Fidler
2
,
Nichola Cooper
3
,
Louise Young
4
Affiliations
1
Imperial College Healthcare NHS Trust, London, W2 1NY, United Kingdom. Electronic address: thomas.gardiner@nhs.net.
2
Department of Infectious Diseases, Faculty of Medicine, Imperial College, London, SW7 2AZ, United Kingdom.
3
Department of Immunology and Inflammation, Faculty of Medicine, Imperial College, London, SW7 2AZ, United Kingdom.
4
Imperial College Healthcare NHS Trust, London, W2 1NY, United Kingdom.
PMID:
33189774
PMCID:
PMC7658557
DOI:
10.1016/j.jinf.2020.11.004
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Arginine / analogs & derivatives
COVID-19*
Ethnicity*
Humans
London
SARS-CoV-2
State Medicine
Substances
Arginine
benzoyl L-arginine methyl ester
Grants and funding
RP-2016-07-012/DH_/Department of Health/United Kingdom